Table 1:
Histologic type, stage, tumor volume and cfDNA concentration of endometrial cancer patients included this study.
| n (%) | Mean tumor volume cm3 (Std Dev) | MSK-IMPACT sequencing primary tumor n (%) | Mean cfDNA concentration pre-op/baseline ng/ml (Std Dev) | MSK-ACCESS sequencing cfDNA pre-op/baseline n (%) | |
|---|---|---|---|---|---|
| Surgical stage | 44 | 42 | 33 | ||
| Stage IA | 30* (68%) | - | 28* (67%) | 2.68 (1.94) | 19* (58%) |
| Stage IB | 4* (9%) | - | 4* (10%) | 4.05 (2.29) | 4* (12%) |
| Stage II | 0 (0%) | - | 0 (0%) | - | 0 (0%) |
| Stage III | 8 (18%) | - | 8 (19%) | 4.78 (2.56) | 8 (24%) |
| Stage IV | 2 (5%) | - | 2 (5%) | 11.61 (12.74) | 2 (6%) |
| MRI stage | 37 | 105.2 (446) | 35 | 24 | |
| No measurable disease | 7 (21%) | 0 (0) | 5 (14%) | 3.03 (1.76) | 4 (17%) |
| Stage IA | 18 (53%) | 14.4 (26) | 18 (51%) | 2.91 (1.89) | 11 (46%) |
| Stage IB | 3 (9%) | 42.2 (47) | 3 (9%) | 6.01 (3.82) | 3 (13%) |
| Stage II | 1 (3%) | 12.6 (NA) | 1 (3%) | 3.10 (NA) | 1 (4%) |
| Stage III | 3 (9%) | 171.7 (128) | 3 (9%) | 4.06 (2.91) | 3 (13%) |
| Stage IV | 2 (6%) | 1332.5 (1804) | 2 (6%) | 11.61 (12.74) | 2 (8%) |
| Histologic type | 44 | 42 | 33 | ||
| Endometrioid | 24 (55%) | 28.7 (73) | 23 (55%) | 2.90 (1.69) | 16 (48%) |
| Serous | 7 (16%) | 16.0 (27) | 7 (17%) | 4.01 (2.45) | 6 (18%) |
| Carcinosarcoma | 6 (15%) | 671.6 (1291) | 6 (14%) | 5.52 (7.63) | 5 (15%) |
| High-grade carcinoma | 4 (9%) | 13.8 (20) | 3 (7%) | 3.58 (2.21) | 3 (9%) |
| Mixed | 1 (2%) | 7.7 (NA) | 1 (2%) | 7.47 (NA) | 1 (3%) |
| De-differentiated | 1 (2%) | 95.4 (NA) | 1 (2%) | 8.89 (NA) | 1 (3%) |
| Adenosarcoma | 1 (2%) | 111.0 (NA) | 1 (2%) | 2.07 (NA) | 1 (3%) |
*
One stage IA and two stage IB cases had isolated tumor cells in the lymph nodes on pathology. cfDNA: cell-free DNA; NA, not available; Std Dev, standard deviation.